Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
ReGenX Biosciences, LLC - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'ReGenX Biosciences, LLC - Product Pipeline Review - 2014', provides an overview of the ReGenX Biosciences, LLC's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of ReGenX Biosciences, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of ReGenX Biosciences, LLC including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of ReGenX Biosciences, LLC's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the ReGenX Biosciences, LLC's pipeline products Reasons to buy - Evaluate ReGenX Biosciences, LLC's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of ReGenX Biosciences, LLC in its therapy areas of focus - Identify new drug targets and therapeutic classes in the ReGenX Biosciences, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of ReGenX Biosciences, LLC and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of ReGenX Biosciences, LLC - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of ReGenX Biosciences, LLC and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 ReGenX Biosciences, LLC Snapshot 5 ReGenX Biosciences, LLC Overview 5 Key Information 5 Key Facts 5 ReGenX Biosciences, LLC - Research and Development Overview 6 Key Therapeutic Areas 6 ReGenX Biosciences, LLC - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 ReGenX Biosciences, LLC - Pipeline Products Glance 14 ReGenX Biosciences, LLC - Clinical Stage Pipeline Products 14 Phase I Products/Combination Treatment Modalities 14 ReGenX Biosciences, LLC - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 ReGenX Biosciences, LLC - Drug Profiles 16 Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Gene Therapy to Activate Factor IX for Hemophilia B 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Gene Therapy to Activate Tripeptidyl Peptidase 1 for Batten Disease 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 AP-22594 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Gene Therapy for Alzheimer's Disease 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Gene Therapy for Wet Age-Related Macular Degeneration 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Gene Therapy to Activate Arylsulfatase B for Maroteaux-Lamy Syndrome 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Gene Therapy to Activate Iduronidase for Hurler Syndrome 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Gene Therapy to Activate LDL Receptor for Homozygous Familial Hypercholesterolemia 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis (LCA) 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ReGenX Biosciences, LLC - Pipeline Analysis 28 ReGenX Biosciences, LLC - Pipeline Products by Target 28 ReGenX Biosciences, LLC - Pipeline Products by Route of Administration 29 ReGenX Biosciences, LLC - Pipeline Products by Molecule Type 30 ReGenX Biosciences, LLC - Pipeline Products by Mechanism of Action 31 ReGenX Biosciences, LLC - Recent Pipeline Updates 32 ReGenX Biosciences, LLC - Locations And Subsidiaries 33 Head Office 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables ReGenX Biosciences, LLC, Key Information 5 ReGenX Biosciences, LLC, Key Facts 5 ReGenX Biosciences, LLC - Pipeline by Indication, 2014 7 ReGenX Biosciences, LLC - Pipeline by Stage of Development, 2014 8 ReGenX Biosciences, LLC - Monotherapy Products in Pipeline, 2014 9 ReGenX Biosciences, LLC - Partnered Products in Pipeline, 2014 10 ReGenX Biosciences, LLC - Partnered Products/ Combination Treatment Modalities, 2014 11 ReGenX Biosciences, LLC - Out-Licensed Products in Pipeline, 2014 12 ReGenX Biosciences, LLC - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 ReGenX Biosciences, LLC - Phase I, 2014 14 ReGenX Biosciences, LLC - Preclinical, 2014 15 ReGenX Biosciences, LLC - Pipeline by Target, 2014 28 ReGenX Biosciences, LLC - Pipeline by Route of Administration, 2014 29 ReGenX Biosciences, LLC - Pipeline by Molecule Type, 2014 30 ReGenX Biosciences, LLC - Pipeline Products by Mechanism of Action, 2014 31 ReGenX Biosciences, LLC - Recent Pipeline Updates, 2014 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.